Sign Up
Stories
FDA Warns of Counterfeit Ozempic
Share
Anti-Obesity Meds' Impact on Allurion Pr...
Biden's $35 Insulin Price Cap
Biopharma Innovations in Obesity and Mus...
Novo Nordisk's Legal Action Against Phar...
Novo's Weight-Loss Pill Launch Challenge...
Overview
API
FDA warns about counterfeit Ozempic due to potential risks to patients, seizing thousands of units and investigating the situation. Despite counterfeit needles, FDA reports five adverse events related to the drug. High demand outpaces Novo's supply, leading to restrictions on certain doses of Wegovy in the US market.
Ask a question
How can the FDA effectively identify and prevent the distribution of counterfeit drugs?
What impact does this have on the reputation of Novo and the healthcare industry?
What measures can be taken to increase the supply of Ozempic to meet the demand?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage